HIGHLIGHTS
Quercis Pharma is a late clinical stage biotech startup with Phase III assets and strong IP extending through 2045.
Clinical progress
Phase 3 program for cancer thrombosis prevention under FDA Special Protocol Agreement.
Clinical progress
Phase 3 program for cancer thrombosis prevention under FDA Special Protocol Agreement.
Clinical progress
Phase 3 program for cancer thrombosis prevention under FDA Special Protocol Agreement.
Multiple Assets
Cancer-associated thrombosis, Sickle Cell Disease, ALS, COPD, viral diseases.
Multiple Assets
Cancer-associated thrombosis, Sickle Cell Disease, ALS, COPD, viral diseases.
Multiple Assets
Cancer-associated thrombosis, Sickle Cell Disease, ALS, COPD, viral diseases.
Strong IP
Patent protection supported by DLA Piper.
Strong IP
Patent protection supported by DLA Piper.
Strong IP
Patent protection supported by DLA Piper.
Leadership
Our leadership team includes pioneers who have guided the approval of more than 50 therapies. Their collective expertise spans global regulatory strategy, drug development, and commercialization — giving Quercis a foundation few biotech companies can match.
Leadership
Our leadership team includes pioneers who have guided the approval of more than 50 therapies. Their collective expertise spans global regulatory strategy, drug development, and commercialization — giving Quercis a foundation few biotech companies can match.
Leadership
Our leadership team includes pioneers who have guided the approval of more than 50 therapies. Their collective expertise spans global regulatory strategy, drug development, and commercialization — giving Quercis a foundation few biotech companies can match.
Advisors
Quercis is advised by some of the world’s most accomplished scientists and clinicians, including leaders who have overseen the registration of 17 cancer drugs. With direct ties to Harvard, ETH Zurich, Cornell, and other top institutions, our team brings unmatched experience, credibility, and reach to advance our mission.
Advisors
Quercis is advised by some of the world’s most accomplished scientists and clinicians, including leaders who have overseen the registration of 17 cancer drugs. With direct ties to Harvard, ETH Zurich, Cornell, and other top institutions, our team brings unmatched experience, credibility, and reach to advance our mission.
Advisors
Quercis is advised by some of the world’s most accomplished scientists and clinicians, including leaders who have overseen the registration of 17 cancer drugs. With direct ties to Harvard, ETH Zurich, Cornell, and other top institutions, our team brings unmatched experience, credibility, and reach to advance our mission.
Global Mission
Committed to responsible pricing and universal access.
Global Mission
Committed to responsible pricing and universal access.
Global Mission
Committed to responsible pricing and universal access.
Next Milestones
Phase 3 readout in cancer thrombosis prevention expected June 2026
Phase 3 readout in cancer thrombosis prevention expected June 2026
Initiation of Phase 3 Sickle Cell Disease Trial
Initiation of Phase 3 Sickle Cell Disease Trial
Initiation of Infectious Disease Phase II trials with Administration for Strategic Preparedness and Response (ASPR)
Initiation of Infectious Disease Phase II trials with Administration for Strategic Preparedness and Response (ASPR)
Strategic collaborations to expand development and access
Strategic collaborations to expand development and access
© 2025 Quercis Pharma. All rights reserved.
Designed by 12y.design
© 2025 Quercis Pharma. All rights reserved.
Designed by 12y.design
© 2025 Quercis Pharma. All rights reserved.
Designed by 12y.design